tetano
Editor, Senior Moderator
BMC Med
. 2024 Jan 10;22(1):14.
doi: 10.1186/s12916-023-03236-4. Risks of digestive diseases in long COVID: evidence from a population-based cohort study
Yuying Ma[SUP] #[/SUP][SUP] 1 2 [/SUP], Lijun Zhang[SUP] #[/SUP][SUP] 1 3 [/SUP], Rui Wei[SUP] 1 [/SUP], Weiyu Dai[SUP] 1 [/SUP], Ruijie Zeng[SUP] 1 4 [/SUP], Dongling Luo[SUP] 5 [/SUP], Rui Jiang[SUP] 1 3 [/SUP], Zewei Zhuo[SUP] 1 [/SUP], Qi Yang[SUP] 1 [/SUP], Jingwei Li[SUP] 1 2 [/SUP], Felix W Leung[SUP] 6 7 [/SUP], Chongyang Duan[SUP] 8 [/SUP], Weihong Sha[SUP] 9 10 11 12 [/SUP], Hao Chen[SUP] 13 14 15 16 [/SUP]
Affiliations
Background: In the post-pandemic era, a wide range of COVID-19 sequelae is of growing health concern. However, the risks of digestive diseases in long COVID have not been comprehensively understood. To investigate the long-term risk of digestive diseases among COVID patients.
Methods: In this large-scale retrospective cohort study with up to 2.6 years follow-up (median follow-up: 0.7 years), the COVID-19 group (n = 112,311), the contemporary comparison group (n = 359,671) and the historical comparison group (n = 370,979) predated the COVID-19 outbreak were built using UK Biobank database. Each digestive outcome was defined as the diagnosis 30 days or more after the onset of COVID-19 infection or the index date. Hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were computed utilizing the Cox regression models after inverse probability weighting.
Results: Compared with the contemporary comparison group, patients with previous COVID-19 infection had higher risks of digestive diseases, including gastrointestinal (GI) dysfunction (HR 1.38 (95% CI 1.26 to 1.51)); peptic ulcer disease (HR 1.23 (1.00 to 1.52)); gastroesophageal reflux disease (GERD) (HR 1.41 (1.30 to 1.53)); gallbladder disease (HR 1.21 (1.06 to 1.38)); severe liver disease (HR 1.35 (1.03 to 1.76)); non-alcoholic liver disease (HR 1.27 (1.09 to 1.47)); and pancreatic disease (HR 1.36 (1.11 to 1.66)). The risks of GERD were increased stepwise with the severity of the acute phase of COVID-19 infection. Even after 1-year follow-up, GERD (HR 1.64 (1.30 to 2.07)) and GI dysfunction (HR 1.35 (1.04 to 1.75)) continued to pose risks to COVID-19 patients. Compared to those with one SARS-CoV-2 infection, reinfected patients were at a higher risk of pancreatic diseases (HR 2.57 (1.23 to 5.38)). The results were consistent when the historical cohort was used as the comparison group.
Conclusions: Our study provides insights into the association between COVID-19 and the long-term risk of digestive system disorders. COVID-19 patients are at a higher risk of developing digestive diseases. The risks exhibited a stepwise escalation with the severity of COVID-19, were noted in cases of reinfection, and persisted even after 1-year follow-up. This highlights the need to understand the varying risks of digestive outcomes in COVID-19 patients over time, particularly those who experienced reinfection, and develop appropriate follow-up strategies.
Keywords: Gastroenterology; Long-COVID; SARS-CoV-2.
. 2024 Jan 10;22(1):14.
doi: 10.1186/s12916-023-03236-4. Risks of digestive diseases in long COVID: evidence from a population-based cohort study
Yuying Ma[SUP] #[/SUP][SUP] 1 2 [/SUP], Lijun Zhang[SUP] #[/SUP][SUP] 1 3 [/SUP], Rui Wei[SUP] 1 [/SUP], Weiyu Dai[SUP] 1 [/SUP], Ruijie Zeng[SUP] 1 4 [/SUP], Dongling Luo[SUP] 5 [/SUP], Rui Jiang[SUP] 1 3 [/SUP], Zewei Zhuo[SUP] 1 [/SUP], Qi Yang[SUP] 1 [/SUP], Jingwei Li[SUP] 1 2 [/SUP], Felix W Leung[SUP] 6 7 [/SUP], Chongyang Duan[SUP] 8 [/SUP], Weihong Sha[SUP] 9 10 11 12 [/SUP], Hao Chen[SUP] 13 14 15 16 [/SUP]
Affiliations
- PMID: 38195495
- PMCID: PMC10777515
- DOI: 10.1186/s12916-023-03236-4
Background: In the post-pandemic era, a wide range of COVID-19 sequelae is of growing health concern. However, the risks of digestive diseases in long COVID have not been comprehensively understood. To investigate the long-term risk of digestive diseases among COVID patients.
Methods: In this large-scale retrospective cohort study with up to 2.6 years follow-up (median follow-up: 0.7 years), the COVID-19 group (n = 112,311), the contemporary comparison group (n = 359,671) and the historical comparison group (n = 370,979) predated the COVID-19 outbreak were built using UK Biobank database. Each digestive outcome was defined as the diagnosis 30 days or more after the onset of COVID-19 infection or the index date. Hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were computed utilizing the Cox regression models after inverse probability weighting.
Results: Compared with the contemporary comparison group, patients with previous COVID-19 infection had higher risks of digestive diseases, including gastrointestinal (GI) dysfunction (HR 1.38 (95% CI 1.26 to 1.51)); peptic ulcer disease (HR 1.23 (1.00 to 1.52)); gastroesophageal reflux disease (GERD) (HR 1.41 (1.30 to 1.53)); gallbladder disease (HR 1.21 (1.06 to 1.38)); severe liver disease (HR 1.35 (1.03 to 1.76)); non-alcoholic liver disease (HR 1.27 (1.09 to 1.47)); and pancreatic disease (HR 1.36 (1.11 to 1.66)). The risks of GERD were increased stepwise with the severity of the acute phase of COVID-19 infection. Even after 1-year follow-up, GERD (HR 1.64 (1.30 to 2.07)) and GI dysfunction (HR 1.35 (1.04 to 1.75)) continued to pose risks to COVID-19 patients. Compared to those with one SARS-CoV-2 infection, reinfected patients were at a higher risk of pancreatic diseases (HR 2.57 (1.23 to 5.38)). The results were consistent when the historical cohort was used as the comparison group.
Conclusions: Our study provides insights into the association between COVID-19 and the long-term risk of digestive system disorders. COVID-19 patients are at a higher risk of developing digestive diseases. The risks exhibited a stepwise escalation with the severity of COVID-19, were noted in cases of reinfection, and persisted even after 1-year follow-up. This highlights the need to understand the varying risks of digestive outcomes in COVID-19 patients over time, particularly those who experienced reinfection, and develop appropriate follow-up strategies.
Keywords: Gastroenterology; Long-COVID; SARS-CoV-2.